Research
Molecular
New pharmacological molecules are likely to be treatment options for patients with rare genetic obesities in the coming years.
Practitioners should stay informed about emerging pharmacological treatments for obesity.
StrongSupportsmedium confidence
Several new pharmacological molecules benefit patients with monogenic or syndromic obesity.
Why this rating
The abstract discusses a narrative review, indicating a comprehensive overview of the topic.
Source
Novel therapeutics in rare genetic obesities: A narrative review
Béatrice Dubern et al. · Pharmacological Research · 2023
DOI 10.1016/j.phrs.2023.106763
reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →